Login to Your Account



arGEN-X Expands Shire Deal; Starts Phase Ib Cancer Trial

By Nuala Moran
Staff Writer

Tuesday, January 8, 2013
LONDON – arGEN-X BV is making strides in the commercialization of its antibody platform, announcing an extension of its existing collaboration with Shire plc in rare diseases and at the same time advancing the lead in-house program into a Phase Ib first-in-man trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription